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Standard chemoradiotherapy with infusional 5FU for locally advanced pancreatic cancer (LAPC) has limited efficacy in this disease.
The combination of Capecitabine (Cap) and Gemcitabine (Gem) are synergistic and are potent radiosensitisers. The aim of this phase
I trial was thus to determine the highest administered dose of the Cap plus Gem combination with radical radiotherapy (RT) for
LAPC. Patients had LAPC, adequate organ function, ECOG PS 0–1. During RT, Gem was escalated from 20–50mgm
 2day
 1
(twice per week), and Cap 800–2000mgm
 2day
 1 (b.i.d, days 1–5 of each week). Radiotherapy 50.4Gy/28 fractions/5.5 weeks,
using 3D-conformal techniques. Three patients were entered to each dose level (DL). Dose-limiting toxicity(s) (DLTs) were based
on treatment-related toxicities. Twenty patients were accrued . Dose level (DL) 1: Cap/Gem; 800/20mgm
 2day
 1 (3 patients),
DL2: 1000/20 (12 patients), DL3: 1300/30 (5 patients). Dose-limiting toxicities were observed in DL3; grade 3 dehydration
(1 patient) and grade 3 diarrhoea and dehydration (1 patient). Dose level 2 was the recommend phase 2 dose. Disease control rate
was 75%: PR¼15%, SD¼60%. Median overall survival was 11.2 months. The addition of Cap and Gem to radical RT was feasible
and active and achieved at relatively low doses.
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The treatment of unresectable locally advanced pancreatic cancer
(LAPC) is challenging (Verslype et al, 2007), given it is
characterised by a median survival of 8–12 months (Kim and
Saif, 2007). The treatment options have included palliative surgery,
chemotherapy or chemoradiotherapy (CRT) (Huguet et al, 2007;
Verslype et al, 2007). The combination of radiotherapy (RT) with
infusional 5FU has been considered by many as the standard of
care. The pivotal trials have shown a survival advantage of CRT
relative to RT or chemotherapy alone (Moertel et al, 1981), albeit
inconsistently (Cohen et al, 2005). A recent meta-analysis has also
confirmed the significant survival advantage of CRT here (Sultana
et al, 2007).
Nevertheless, alternative drugs for radiosensitisation and
systemic control are required to improve outcome. Gemcitabine
(Gem) is a potent radiosensitiser, (Lawrence et al, 1996) and a
number of phase I trials have thus far combined this agent with RT
for LAPC (Blackstock et al, 1999; Talamonti et al, 2000; Wolff et al,
2001; Epelbaum et al, 2002; Yamazaki et al, 2004; Pipas et al, 2005;
Brade et al, 2007). A phase III trial in patients with LAPC has also
directly compared Gem alone vs weekly Gem concurrent with
radical radiation therapy followed by further Gem therapy
(Loehrer et al, 2008).
Studies in pancreatic cell lines (Lawrence et al, 1996), and in
murine squamous cell carcinoma models (Fields et al, 2000), have
confirmed that minimal cytotoxic doses are required for radio-
sensitivity and which persists for 48h after administration. Hence,
drug administration more than once per week during RT may be
beneficial (Lawrence et al, 1996; Fields et al, 2000; Blackstock et al,
2003; Brade et al, 2007).
The utility of Capecitabine (Cap) with radiation in LAPC has
also been assessed. The final step in its activation to 5FU is
catalysed by thymidine phosphorylase (TP). Higher levels of TP
are found in malignant cells resulting in preferential tumoral
activation, and its expression has been correlated with an objective
response to Cap-based regimens (Eda et al, 1993). Thymidine
phosphorylase is also upregulated by cytotoxics, as well
as radiation (Sawada et al, 1999). It has been combined with
RT for LAPC in a number of trials using various schedules
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s(Schneider et al, 2005; Crane et al, 2006; Saif et al, 2007). The
combination of Cap and Gem has also shown superiority to Gem
alone in a phase III trial of patients with advanced disease
(Cunningham et al, 2005).
Given the synergy between Gem and Cap and their respective
radiosensitisation, the primary objective of this phase I trial was
therefore to determine for the first time the highest administered
dose of oral Cap combined with twice weekly Gem and radical RT
in patients with LAPC. The secondary objectives were to determine
its safety profile and response.
PATIENTS AND METHODS
Patient selection
Inclusion criteria The following patients were eligible: (i) histolo-
gical/cytological confirmation of LAPC that was either deemed
unresectable by specialist hepatobiliary surgeon(s) due to disease
extent or recurrent following surgical resection; (ii) disease suitable
for radical RT (primary tumour o5cm diameter); (iii) measurable or
evaluable disease; (iv) age X18 years; (v) ECOG performance status
0–1; (vi) adequate organ function: bone marrow – haemoglobin
X90gl
 1, neutrophil count X1.5 10
9l
 1, platelet count
X100 10
9l
 1; hepatic – serum bilirubin p1.5  upper limit
normal (ULN), AST and/or ALT p3.0 ULN; renal – creatinine
clearance X50mlmin
 1; (vii) written informed consent.
Exclusion criteria The following patients were ineligible: (i)
distant metastases, (ii) prior chemotherapy or RT, (iii) significant
underlying medical condition(s) that may be aggravated by the
study treatment, (iv) conditions associated with the inability to
swallow, tolerate or absorb oral medication.
The trial protocol was approved by the Ethics Committees of the
treating institutions.
Radiation therapy
Total dose and technique A total of 50.4Gy in 28 fractions,
1.8Gy/fraction, 5 fractions a week, in 5.5 weeks was planned.
Patients were treated using 3D-conformal techniques in accor-
dance with ICRU50/62 recommendations. All fields were treated
on treatment days with 6MeV or higher energy machine.
Radiotherapy target volumes The gross tumour volume (GTV)
was defined on axial CT slices and included the gross primary
tumour and involved lymph nodes (41cm). During the period of
this study, routine IV or oral contrast was not given during the
radiotherapy-planning scan. However, the GTV was delineated
with the aid of diagnostic CT scans performed with IV and oral
contrast.
The clinical target volume (CTV)¼GTV. Prophylactic irradia-
tion of uninvolved lymph node regions was not undertaken.
The planning target volume (PTV)¼CTVþ1cm.
Dose constraints to critical organs at risk The following dose
constraints were used: (i) kidney; dose to one-third of either
kidney was not to exceed 35Gy, dose to two-thirds of either kidney
not to exceed 20Gy, and the mean dose to either kidney should not
to exceed 23Gy; (ii) liver; dose to one-third of liver was not to
exceed 50Gy, dose to two-thirds of liver not to exceed 35Gy, and
the mean dose to liver not to exceed 31Gy; (iii) spinal cord; the
maximum dose to the spinal cord was not to exceed 45Gy.
Simulation Patients were simulated in the supine position.
Simulation of CT with CT slices at 5mm intervals from top of
T11 vertebra to the bottom of L4. Dose volume histograms for liver
and kidney were generated.
Verification Beam eye view simulation films were required for
angled fields. Weekly check films were performed.
Dose modifications for radiotherapy Radiotherapy, together with
chemotherapy, was suspended for any grades 3–4 radiation-
associated toxicities, and recommenced once they had improved to
pgrade 1. Further chemotherapy, at reduced dose, was not given
unless considered to be in the patient’s best interest. If the RT was
interrupted for 2 or more weeks, all therapy was ceased.
Chemotherapy
Concurrent chemotherapy and dose escalation Cap was given
orally twice a day from Monday to Friday. The morning dose was
taken approximately 2h before RT, with the second dose 12h
afterwards. Doses omitted because of toxicity were not replaced.
Gem was to be given twice a week, on Monday and Thursday of
RT, administered over 30min within 2h of delivery of RT.
Antinauseant premedication was given as per institutional
practice.
Both Cap and Gem were planned to be dose escalated in up to 8
dose levels (DLs), with doses ranging from 800 to
2000mgm
 2day
 1 (b.i.d, Monday to Friday) and 20–50mgm
 2
(Monday and Thursday), respectively. Chemotherapy after RT was
not mandated.
Dose-limiting toxicities Dose-limiting toxicities were defined
prospectively using the NCI-CTC (version 2, April 1999), and
based on toxicities experienced during and within 2 weeks
following CRT. The DLTs were: (i) grade 4 neutropenia (ANC
o0.5 10
9l
 1) of any duration, (ii) grade 4 thrombocytopenia
(platelet count o10 10
9l
 1) or grade 3 thrombocytopenia
(platelet count 10–49 10
9l
 1) with bleeding, (iii) febrile neu-
tropenia, (iv) grade 3 or 4 non-haematological toxicity (within or
outside the radiation field) including nausea and vomiting despite
adequate therapy, but excluding alopecia, (v) toxicity requiring
X1 dose reductions during CRT, (vi) 41 week delay in RT.
Dose escalation Three patients were planned to be entered into
each DL and the dose escalation/expansion schema was standard.
If no DLTs were observed in these three patients, the next DL was
opened. If DLTs were observed in one of three patients, then three
additional patients (total of six) were accrued at this DL. If DLTs
were observed in one of six patients, the next DL was opened. If
DLTs were observed in X2 of 3 or 6 patients, no further dose
escalation occurred.
Escalation to the next DL occurred once all three or six patients
had reached the 2-week point after CRT. The highest administered
dose was defined as that DL in which two or more of three or six
patients had DLTs. The recommended phase 2 dose (RP2D) level
(1 below the highest administered dose) was expanded to a total of
12 patients to obtain further data regarding toxicities and
response.
Dose modifications for concurrent chemotherapy During CRT, the
chemotherapy doses were modified based on the worst toxicity
grades. Treatment modification was in two forms, either
permanent dose reductions or treatment deferral with the
recommencement at a reduced dose on recovery. Patients entered
at DL1 requiring more than 1 dose reduction or entered at higher
DLs requiring more than 2 dose reductions discontinued
chemotherapy, but the RT continued.
Treatment was stopped early due to either disease progression, a
42 week delay in RT delivery, unacceptable toxicity or patient
request.
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Within 4 weeks of trial entry, patients underwent a CT scan of the
chest/abdomen/pelvis, with dedicated pancreatic views. Patients
were not staged by endoscopic ultrasound. Within 1 week of trial
entry, patients had blood taken for haematology (full blood
examination (FBE)), biochemistry (creatinine, urea and electro-
lytes, liver function tests) and Ca19-9.
During CRT, patients were evaluated weekly for toxicity by both
radiation and medical oncologists, blood taken for biochemistry
(weekly) and FBE (Mondays and Thursdays). Compliance with
study medications was also assessed. On completion of treatment,
patients were reviewed two weekly for 6 weeks for toxicities, and
restaged with CT scan, and Ca19-9 level. Patients were subse-
quently reviewed every 2 months until progression.
Statistical analysis
Patient baseline characteristics, treatment delivery details and
protocol deviations were summarised using descriptive statistics.
Acute toxicities graded using the NCI-CTC (version 2.0, 30 April
1999) and late radiation toxicities graded using the RTOG criteria
were summarised by DL. Response was assessed by the RECIST
criteria. The best response to treatment, sites of relapse or
progression and status at last follow-up were summarised for each
DL.
Overall survival (OS) was measured from the date of protocol
treatment commencement to the date of death from any cause. The
Kaplan–Meier product limit method was used to estimate OS, with
censoring of survival times at the close-out (censor) date for those
patients still alive. Statistical analyses were performed using S-Plus
2000 Professional software (MathSoft Inc., Seattle, WA, USA,
1999).
RESULTS
Patients
A total of 20 patients were recruited from between November
2002–August 2006, across five centres. Their demographics are
summarised in Table 1. The cohort was recruited across DL1-3, as
follows: (a) DL1 (Cap 800mgm
 2day
 1, Gem 20mgm
 2), three
patients, (b) DL2 (Cap 1000mgm
 2day
 1, Gem 20mgm
 2),
initially three patients and then expanded to a total of 12 patients
and (c) DL3 (Cap 1300mgm
 2day
 1, Gem 30mgm
 2), five
patients.
Treatment delivery
Radiotherapy Fourteen patients (70%) received protocol treat-
ment; 3 of 3 from DL1, 7 of 12 from DL2 and 4 of 5 from DL3. One
patient (DL2) received an additional two fractions of RT to a total
dose of 54Gy/30 fractions. Five patients (25%) received fewer than
the protocol specified 28 fractions of RT, the reasons were as
follows:
(a) DL2: (i) one patient, 19.8Gy/11 fractions, due to opiate-
induced collapse and pneumonia resulting in admission and
omission of all treatment from week 3; (ii) one patient,
37.8Gy/21 fractions, 4 day break in RT due to nausea (grade
3), diarrhoea (grade 2) and pain; (iii) one patient each missed
1 and 2 fractions, respectively, for unspecified reasons.
(b) DL3: one patient, 36.0Gy/20 fractions due to lethargy and
diarrhoea (grade 3).
Concurrent chemotherapy Dose level 3 was identified as the
highest administered DL. Hence, DL2 was identified as the RP2D
and expanded to a total of 12 patients.
Nine patients (45%) received all planned chemotherapy; 2 of 3
from DL1, 6 of 12 from DL2 and 1 of 5 from DL3. The dose
omission/reductions were as follows:
(a) DL1: one dose of Gem omitted on day 1, week 6.
(b) DL2: (i) one patient: Cap ceased from week 5 due to grade 3
nausea and grade 2 diarrhoea; (ii) one patient: Cap omitted in
weeks 4 and 5 due to grade 2 nausea; (iii) two patients for
other non-trial-related reasons; (iv) one patient for nausea and
vomiting in week 1 and diarrhoea in weeks 2 and 4; (v) one
patient with one dose of Gem omitted (week 2) by own choice.
(c) DL3: (i) one patient due to non-neutropenic grade 2 fever in
week 5 of CRT, chemotherapy was discontinued but RT was
completed; (ii) one patient due to grade 3 diarrhoea in week 1,
with a dose reduction of Cap in weeks 2 and 3 and then its
cessation; (iii) one patient with one dose of Cap omitted in
weeks 5 and 6, and one dose of Gem omitted in week 4 (public
holiday) and in week 6; (iv) one patient with one dose each of
Gem and Cap omitted in week 2 due to public holiday.
The average overall relative dose intensity (actual dose delivered
as a percentage of the planned dose) was 90.8% (s.d.¼20.6%) for
Cap and 92.3% (s.d.¼18.0%) for Gem. At the RP2D, the relative
dose intensity was 92.6% (s.d.¼20.1%) for Cap and 94.7%
(s.d.¼19.9%) for Gem.
Dose-limiting toxicities
Dose-limiting toxicities were reported in two patients, both in DL3:
(i) one patient with treatment-related grade 3 dehydration, onset
38 days from the start of treatment and (ii) one patient with grade
3 diarrhoea, onset 4 days from the start of treatment, with a dose
reduction of Cap in weeks 2 and 3 and its cessation subsequently.
Dose level 3 was thus identified as the highest administered dose.
Toxicity
The acute haematological and non-haematological toxicities from
day 1 of CRT till 6 weeks post-completion are detailed in Tables 2
and 3, respectively and were not unexpected. Overall, the CRT was
well tolerated, where two patients (10%) had suffered grade 3
diarrhoea and one patient (5%) each nausea, vomiting and
abdominal pain.
Late radiation toxicities were reported in two patients: one
patient in DL1 with the onset of grade 1 small/large intestine
Table 1 Patient characteristics
Parameter Category N %( N¼20)
Gender Male 12 60%
Female 8 40%
Age at registration (years) Median 64
Range 41–80
Pancreatic subsite Head 19 95%
Body 1 5%
T stage
a 1 2 10%
2 8 40%
3 6 30%
4 4 20%
N stage 0 10 50%
1a 1 5%
1b 5 25%
X 4 20%
Earlier surgery Yes 17 85%
No 3 15%
Baseline Ca19-9 (kUl
 1) Median 366
Range 13–6546
aUICC TNM 5th edition, 1997.
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stoxicity 148 days from the start of the RT, and the other patient in
DL2 with onset of grade 2 liver toxicity 121 days from the start of
RT. The latter patient had acute hepatic toxicity, with an elevated
ALP and AST (12.4  and 2.5  ULN, respectively) 3 weeks post-
completion of treatment. These changes persisted till 12 weeks
post-treatment (6.3  and 1.4  ULN, respectively) and eventually
normalised by 16 weeks. There were no related symptoms.
Response
Three patients (15%) had a partial response (one at DL1 and two at
DL3), 12 patients (60%) had a response of stable disease and four
(20%) had progressive disease; one patient was non-evaluable
(Table 4).
Overall, 15 patients were evaluable for Ca-19-9 response. Two
patients (13.3%) had achieved X50% reduction relative to the
baseline value, 10 patients (67.7%) had stabilisation (o50%
reduction to o25% increase) and 3 patients (20%) had progres-
sion (430% increase).
Survival parameters
One patient of the 20 was still alive on the close-out date of 29
October 2007. The median OS was estimated at 11.2 months (95%
confidence interval 9.4–14.4 months) (Figure 1).
Sites of relapse
Ten patients (50%) were reported to have relapsed or progressed,
five involving distant metastases, three involving primary relapse,
one involving nodal relapse and one combined primary and
distant failure. Five patients received further chemotherapy on
progression.
DISCUSSSION
Given the synergy of Gem and Cap combinations (Cunningham
et al, 2005), and their respective radiosensitisation, the aim of this
trial was to identify for the first time the highest dose of these
agents given concurrently with radical radiation in patients with
LAPC. In this trial, DL2 (Cap 1000mgm
 2day
 1, Gem 20mgm
 2
2  per week) was determined to be the recommended DL,
achieving a relative dose intensity of over 90% for both agents with
good overall tolerance. It must be noted that the doses achieved
here in this combination are approximately 50–60% of that
achieved when each agent has been given alone with radical RT
(Blackstock et al, 1999, 2003; Saif et al, 2005, 2007; Brade et al,
2007; Loehrer et al, 2008).
It must also be noted that Gem has marked schedule dependency
in terms of its toxicity profile and maximal tolerated dose: whether
given alone or in combination with radiotherapy (Martin et al,
1996). Studies in experimental models (Lawrence et al,1 9 9 6 ;F i e l d s
et al, 2000) have confirmed that minimal cytotoxic doses are
required for radiosensitivity and persist for 48h after administra-
tion. Hence, drug administration more than once per week during
RT, as given in this trial, may be beneficial (Lawrence et al, 1996;
Fields et al, 2000; Blackstock et al, 2003; Brade et al,2 0 0 7 ) .H o w e v e r
other schedules of Gem have been combined with external
beam radiotherapy (50.4Gy) as discussed above. This has included
Table 3 Haematological toxicities observed during concurrent chemo-
radiotherapy and 6 weeks post (NCI-CTC Version 2, 30 April 1999)
Dose level
Toxicity
Worse
grade
1
(N¼3)
2
(N¼12)
3
(N¼5)
Total
(%)
Haemoglobin 2 0 4 2 6 (30)
Platelet count 2 0 2 2 4 (20)
Leucocytes 3 0 0 3 3 (15)
Neutrophils 3 0 0 1 1 (5)
Table 4 Radiological response following the completion of all therapies
Dose level
Response
parameters
1
(N¼3)
2
(N¼12)
3
(N¼5)
Total
patients (%)
Overall best response
Complete response 0 0 0 0 (0)
Partial response 1 0 2 3 (15)
Stable disease 2 8 2 12 (60)
Progressive disease 0 3 1 4 (20)
Not evaluable 0 1 0 1 (5)
Table 2 Non-haematological toxicities observed during concurrent
chemoradiotherapy and 6 weeks post (NCI-CTC Version 2, 30 April 1999)
Dose level
Toxicity
Worse
grade
1
(N¼3)
2
(N¼12)
3
(N¼5)
Total
(%)
Diarrhea 3 0 1
a 1 2 (10)
Fatigue 3 0 1 2 3 (15)
Anorexia 3 0 0 1 1 (5)
Dehydration 3 0 0 2 2 (10)
Nausea 3 0 1 0 1 (5)
Vomiting 3 0 1 0 1 (5)
Abdominal pain 3 0 1 0 1 (5)
Radiation dermatitis 1 0 1 1 2 (10)
Dyspepsia/heartburn 2 1 0 1 2 (10)
Bilirubin 4 0 1 0 1 (5)
ALT 3 0 1 0 1 (5)
Hypokalaemia 3 0 1 3 4 (20)
Note patients may have had more than one concurrent toxicity.
aNot considered as
treatment related by the investigator.
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Figure 1 Kaplan–Meier curve of overall survival for all 20 patients.
Ninety-five percent confidence intervals are shown by dotted lines. Patients
with censored times are shown by tick marks.
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sa weekly regimen, where doses ranging from 250–600mgm
 2 per
week have been evaluated. These doses approach active systemic
exposures of the agent, but as well, may potentially provide greater
radiosensitisation with 50.4Gy radiation compared with a twice
weekly schedule (Epelbaum et al, 2002; Okusaka et al, 2004; Cengiz
et al, 2007; Loehrer et al,2 0 0 8 ) .
The inability to dose escalate was not a reflection of the trial
design. The dose escalation plan here was standard, the DLTs were
pragmatic and corresponded to clinically significant treatment-
related toxicities and the patients were carefully reviewed. This
inability was most likely due to these agents providing at least an
additive radiosensitisation when given together with radical
radiation.
There are other examples of this in the literature. A recent phase
I trial attempted to dose escalate Gefitinib, a potent radiosensitiser,
and Cap with RT in patients with LAPC (Czito et al, 2006). In this
study, three of seven patients at DL1 (Gefitinib 250mgday
 1,
Cap 650mgm
 2/b.i.d. continuously) and all of three at DL2
(250mgday
 1 and 825mgm
 2/b.i.d.) developed a DLT comprising
of grades 3–4 gastrointestinal toxicity (Czito et al, 2006). Similarly,
a phase I trial combined twice weekly Gem and cisplatin for 3
weeks during RT (50.4Gy/28 fractions) in patients with LAPC or
gastric cancer (Martenson et al, 2003). The highest tolerated dose
was DL5 (Gem 30mgm
 2 and cisplatin 10mgm
 2) (Martenson
et al, 2003). It thus appears that the dose escalation of two active
cytotoxic radiosensitisers is limited in the setting of CRT for LAPC,
possibly related to the dose-limiting normal structures within the
target volume.
The regimen was overall well tolerated and the toxicity
profile concurs with CRT studies using either agent alone (Table 3)
(Blackstock et al, 1999, 2003; Ben-Josef et al, 2004; Saif et al, 2005;
Brade et al, 2007). The low rates of GI toxicity observed
reflected the weekly review during CRT, the DL achieved and
importantly the use of 3D-conformational radiation fields in an
effort to spare the dose-limiting normal structures including the
small bowel. Although not directly shown in this study, it is more
likely that the use of such multifield radiation techniques will
produce less toxicity compared with anteroposterior–postero-
anterior techniques used in some previously reported studies
(Talamonti et al, 2000; Wolff et al, 2001; Goldstein et al, 2007). The
treatment of smaller volumes covering only gross disease is also
more likely to produce less toxicity compared with larger volumes
that include prophylactic irradiation of uninvolved regional lymph
nodes.
In a phase I trial by ECOG, seven patients with LAPC were
treated with radiation (59.4Gy) and infusional 5FU with Gem
doses escalated from 50 to 100mgm
 2 per week. Three patients
developed upper gastrointestinal ulceration with severe bleeding,
and three of the five episodes of DLT developed at radiation doses
p36Gy (Talamonti et al, 2000). The treatment volume encom-
passed the tumour with a 2-cm margin, and a dose of 45Gy was
delivered to all of the at-risk regional lymph nodes (Talamonti
et al, 2000). In the trial reported here, a specific 3D-conformal RT
technique was used and the RT target volumes did not include the
treatment of uninvolved regional lymph nodes.
As this was a phase I trial with a small cohort size, response and
survival were not primary end points and hence caution must be
given in their interpretation. The response rate was consistent with
those reported by CRT trials evaluating bi-weekly Gem alone
(Pipas et al, 2001; Brade et al, 2007; Loehrer et al, 2008), or similar
Cap regimens (Saif et al, 2005), and similarly for survival times
(Blackstock et al, 1999; Epelbaum et al, 2002; Poggi et al, 2002;
Brade et al, 2007; Saif et al, 2007; Loehrer et al, 2008). Hence, it
cannot be concluded that the CRT combination evaluated here
provided a greater activity than either agent alone due to limited
dose escalation. Further advances may be achieved by the addition
of biological agents to enhance radiosensitisation (Krempien et al,
2007; Small et al, 2008).
Despite achieving local control, the majority of LAPC patients
relapse distantly, as observed in this trial. In this cohort, patients
were not mandated to have a screening laparascopy to exclude
peritoneal disease. It also implies that adequate systemic control
and the identification of patients who are more likely to progress
early are essential steps to improve survival with this multi-
modality approach.
Given the limited modest success with current systemic
regimens (Cunningham et al, 2005; Kindler et al, 2007; Moore
et al, 2007), alternative approaches are required. The identification
of patients more likely to respond to chemotherapy or CRT is one
approach. At present, there is a paucity of reliable consistent
genetic data in this regard (Ogawa et al, 2006). In one promising
study of patients with resectable pancreatic adenocarcinoma,
treated with neoadjuvant concurrent Gem and RT, polymorphisms
in the DNA damage response/repair genes were observed to have
had a significant impact on the OS (Po0.02) (Li et al, 2006).
One alternative approach has been the selecting out those
patients who would progress early with an upfront CRT approach.
For example, initial induction chemotherapy followed by CRT in
those patients who had not progressed. A retrospective analysis of
patients with LAPC enrolled into two studies compared the
survival of those treated with initial chemotherapy and then in the
absence of progression who received CRT, with that of patients
who continued with chemotherapy alone. After initial control by
chemotherapy, CRT had significantly improved survival compared
with further chemotherapy alone: the median progression-free
survival times were 10.8 vs 7.4 months (P¼0.005), and the median
OS times 15.0 and 11.7 months, respectively (P¼0.0009) (Huguet
et al, 2007). It is still unclear if induction chemotherapy followed
by CRT is superior to CRT alone.
In conclusion, the addition of Cap and Gem to radical RT was
feasible and tolerable in patients with LAPC. The recommended
dose was Cap 1000mgm
 2day
 1 and Gem 20mgm
 2day
 1 (twice
per week) when combined with 50.4Gy. The efficacy of this
regimen will require testing in the phase II setting.
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